Tags : Commercialize


AstraZeneca Collaborates with Junshi to Commercialize Toripalimab in China

Shots: AstraZeneca to get exclusive promotion rights for toripalimab in mainland China for the urothelial carcinoma indications and all indications in non-core areas Junshi will continue responsible for the promotion of other approved indications and to be approved excluding urothelial carcinoma in core areas The companies will continue to explore overseas business collaborations including emerging […]Read More


Kamada to Commercialize Three Biosimilar Products in Israel

Shots: Kamada signs an agreement with two undisclosed international pharmacies to commercialize three biosimilar product candidates in Israel. The two pharmaceutical companies will be responsible for the development, manufacturing, and supply of three products Following the approval from EMA and IMOH, the three products are expected to be launched in Israel b/w 2022 and 2024 […]Read More


Y-Biologics Signs a License Agreement with 3D Medicines for YBL-013

Shots: Y-Biologics to receive ~$2M up front and eligible to receive ~$85M as development, regulatory, & commercialization milestones along with royalties on sales in the territory 3D Medicines will get an exclusive right to develop, manufacture, and commercialize YBL-013 in China with the expansion of collaboration in the US and other regions Both the companies […]Read More


Myovant Signs Agreement with Pfizer to Develop and Commercialize Relugolix

Shots: Myovant & Pfizer will jointly develop & commercialize ORGOVYX (relugolix) in advanced prostate cancer & if approved, relugolix combination tablet in women’s health in the US & Canada. Myovant will receive ~$4.2B including $650M upfront, $200M in regulatory milestones for FDA approvals for relugolix combination tablet in women’s health, and tiered sales milestones upon […]Read More


GSK Signs an Exclusive License Agreement with Surface Oncology to

Shots: Surface Oncology to receive ~$85 M upfront and ~$730 M as milestones along with royalties on net sales of SRF813 GSK to get an exclusive right to develop and commercialize Surface Oncology’s preclinical program, SRF813 SRF813 is an IgG1 Ab targeting PVRIG (also k/a CD112), currently in IND-enabling studies with anticipated IND submission in […]Read More


Bio-Thera Collaborates with Biomm to Commercialize BAT1706 (biosimilar, bevacizumab) in

Shots: Biomm to get exclusive rights to distribute & market the therapy in Brazil. Bio-Thera will be responsible for development & commercial supply of BAT1706 out of its manufacturing facilities in Guangzhou, China Bio-Thera’s BAT1706 has completed a global P-III comparative clinical study assessing the efficacy, safety, PK and immunogenicity of BAT1706 vs EU-bevacizumab + […]Read More


Schrödinger Signs a $2.7B Agreement with BMS to Develop and

Shots: Schrödinger to receive $55M upfront and is eligible to receive $2.7B as preclinical, development, regulatory & commercial milestones along with royalties on sales of each product commercialized by BMS Schrödinger to grant BMS exclusive WW rights to develop & commercialize the development candidates emerges from the collaboration The collaboration will merge Schrödinger’s computational platform […]Read More


Novartis Signs a License Agreement with Mesoblast to Develop and

Shots: Mesoblast to receive $25M up front and $25M as equity investment with additional payments and royalties on achievement of development, regulatory and commercial milestones Novartis to acquire the exclusive WW rights to develop, commercialize & manufacture remestemcel-L for ARDS & access to a cell-therapy based platform with WW rights to a range of potential […]Read More


Prestige Signs an Exclusive Agreement with Teva to Commercialize Tuznue

Shots: Teva to get an exclusive right to commercialize Tuznu in Israel, leveraging its marketing capabilities and experience in bringing pharmaceutical products to market and will be responsible for local registration, sales, and marketing in Israel Prestige will assume responsibility for product registration with the EMA and commercial supply of Tuznue from its manufacturing facilities […]Read More